Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2015

View Archived Issues

Preliminary data reported from phase I/IIa study of third-generation CAR T cells targeting CD19

SVN-2B peptide vaccination shows promise for gastrointestinal cancer

Phase I clinical trial shows promising results for TIL 1383I transduced T cells

JCR and Sumitomo Dainippon Pharma enter feasibility agreement in psychiatry and neurology

Avalon Ventures and GSK launch new companies Adrenergics, CadheRx and Calporta

Queensland Emory Drug Discovery Initiative announced

Once-weekly LAPSInsulin Combo shows better glycemic control, reduced side effects

Eppin Pharma receives NIH grant to develop non-hormonal male contraceptive

FDA approves Zomig Nasal Spray for patients aged 12-17 years

Novartis to develop inhaled indacaterol/glycopyrronium bromide/mometasone furoate

Teva releases topline data from pivotal study of SD-809 for tardive dyskinesia

FDA clears IND for U.S. study of GTL-001 HPV therapeutic vaccine candidate

Novel gene therapy shows promising results in mouse models of Friedreich's ataxia

Fagron licenses U.S. rights to OMS-103 from Omeros

OncoSec Medical starts phase II study of ImmunoPulse in HNSCC

AveXis licenses rights to AskBio's AAV Duplex vector technology for use in SMA gene therapy

Admune Therapeutics starts phase I trial of hetIL-15 in metastatic cancers

Aimmune Therapeutics receives FDA breakthrough therapy designation for AR-101

Roche and Genentech introduce BTK inhibitors

Lead Pharma patents RORgamma modulators

Sichuan Haisco discloses FXa inhibitors

Jiangsu Aosaikang discloses EGFR inhibitors

Beijing JenKem presents EGFR inhibitors for AD

World Sickle Cell Day: LentiGlobin gene therapy continues to impress in clinical study

Allergan to acquire Kythera Biopharmaceuticals

Tribute Pharmaceuticals acquires Medical Futures

Akashi Therapeutics reports data on HT-100 in patients with DMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...